Advanced screening assays to rapidly identify solubility-enhancing formulations: High-throughput, miniaturization and automation

Advanced Drug Delivery Reviews

Volumn 60, Issue 6, 2008, Pages 657-672

  Dai, Wei Guo ^a   Pollock Dove, Crystal ^a   Dong, Liang C ^a   Li, Shu ^a  

^a ALZA CORPORATION   (United States)

Author keywords

Automation; Formulation; High throughput; Miniaturization; Screening assay; Solubility

Indexed keywords

AUTOMATION; DRUG PRODUCTS; SOLUBILITY;

ACTIVE PHARMACEUTICAL INGREDIENTS (API); MINIATURIZATION; SCREENING ASSAYS;

BIOASSAY;

ALBENDAZOLE; AMIODARONE; CELECOXIB; DANAZOL; DIGOXIN; DIPYRIDAMOLE; EFAVIRENZ; ESTRADIOL; EXCIPIENT; GEFITINIB; GRISEOFULVIN; IVERMECTIN; KETOPROFEN; LANSOPRAZOLE; LEVOTHYROXINE; LORATADINE; NIFEDIPINE; PACLITAXEL; PHENYTOIN; PRAZOSIN; PROGESTERONE; PROPOFOL; PROPRANOLOL; RESERPINE; SIMVASTATIN; SOLVENT; SURFACTANT; TAMOXIFEN; TOLNAFTATE; UNINDEXED DRUG;

AQUEOUS SOLUTION; AUTOMATION; COMPLEX FORMATION; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; ELECTRONICS; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; NEPHELOMETRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SELF EMULSIFYING FORMULATION; THERMODYNAMICS; TURBIDIMETRY; ULTRAVIOLET SPECTROSCOPY;

AUTOMATION; CHEMISTRY, PHARMACEUTICAL; KINETICS; MINIATURIZATION; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SOLVENTS; THERMODYNAMICS;

EID: 39149095938     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.10.017     Document Type: Review

References (59)

1. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
2. Prentis R.A., Lis Y., and Walker S.R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25 (1988) 387-396
3. Kim C.-K., and Park J.-S. Solubility enhancers for oral drug delivery: can chemical structure manipulation be avoided?. Am. J. Drug Deliv. 2 (2004) 113-130
4. M.V. Chaubal. Rapid screening of excipients to develop effective formulations, Drug Deliv. Technol. 5 (2005) 40, 42.
5. Bittner B., and Mountfield Richard J. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Opin. Drug Discov. Dev. 5 (2002) 59-71
6. Gardner C. Drug candidate selection: the role of physical chemistry and material science in form and formulation. Bull. Tech. Gattefosse (2005) 9-18
7. Carlson E.D., Cong P., Chandler Jr. W.H., Chau H.K., Crevier T., Desrosiers P.J., Doolen R.D., Freitag C., Hall L.A., Kudla T., Luo R., Masui C., Rogers J., Song L., Tangkilisan A., Ung K.Q., and Wu L. An integrated high throughput workflow for pre-formulations: polymorph and salt selection studies. Pharma. Chem. 2 (2003) 10-15
8. Gardner C.R., Almarsson O., Chen H., Morissette S., Peterson M., Zhang Z., Wang S., Lemmo A., Gonzalez-Zugasti J., Monagle J., Marchionna J., Ellis S., McNulty C., Johnson A., Levinson D., and Cima M. Application of high throughput technologies to drug substance and drug product development. Comput. Chem. Eng. 28 (2004) 943-953
9. Gardner C.R., Walsh C.T., and Almarsson O. Drugs as materials: valuing physical form in drug discovery. Nat. Rev. Drug Discov. 3 (2004) 926-934
10. Morissette S.L., Almarsson O., Peterson M.L., Remenar J.F., Read M.J., Lemmo A.V., Ellis S., Cima M.J., and Gardner C.R. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv. Drug Deliv. Rev. 56 (2004) 275-300
11. Kerns E.H. High throughput physicochemical profiling for drug discovery. J Pharm. Sci. 90 (2001) 1838-1858
12. Lipper R.A. How can we optimize selection of drug development candidates from many compounds at the discovery stage?. Mod. Drug Discov. 2 (1999) 55-60
13. Amidon G.L., Lennernaes H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
14. Avdeef A. High-throughput measurements of solubility profiles. Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies, [LogP2000, Lipophilicity Symposium], 2nd (2001), Lausanne, Switzerland 305-325
15. C.D. Bevan, R.S. Lloyd, A high-throughput aqueous drug solubility by laser nephelometry, in B. Testa, H. van de Waterbeemd, G. Folkers, R. Guy, et al (Eds.), Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies, University of Lausanne, 2000, p. 655.
16. Bevan C.D., and Lloyd R.S. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal. Chem. 72 (2000) 1781-1787
17. Chen T.-M., Shen H., and Zhu C. Evaluation of a method for high throughput solubility determination using a multi-wavelength UV plate reader. Comb. Chem. High Throughput Screen. 5 (2002) 575-581
18. Dehring K.A., Workman H.L., Miller K.D., Mandagere A., and Poole S.K. Automated robotic liquid handling/laser-based nephelometry system for high throughput measurement of kinetic aqueous solubility. J. Pharm. Biomed. Anal. 36 (2004) 447-456
19. Fligge T.A., and Schuler A. Integration of a rapid automated solubility classification into early validation of hits obtained by high throughput screening. J. Pharm. Biomed. Anal. 42 (2006) 449-454
20. Pan L., Ho Q., Tsutsui K., and Takahashi L. Comparison of chromatographic and spectroscopic methods used to rank compounds for aqueous solubility. J. Pharm. Sci. 90 (2001) 521-529
21. Ruell J.A., Avdeef A., Du C., and Wagner S. High-throughput solubility methods for small molecules, Abstracts of Papers. 224th ACS National Meeting, Boston, MA, United States, August 18-22, 2002 (2002) MEDI-164
22. Seadeek C., Ando H., Bhattachar S.N., Heimbach T., Sonnenberg J.L., and Blackburn A.C. Automated approach to couple solubility with final pH and crystallinity for pharmaceutical discovery compounds. J. Pharm. Biomed. Anal. 43 (2007) 1660-1666
23. Sugano K., Kato T., Suzuki K., Keiko K., Sujaku T., and Mano T. High throughput solubility measurement with automated polarized light microscopy analysis. J. Pharm. Sci. 95 (2006) 2115-2122
24. Sugaya Y., Yoshiba T., Kajima T., and Ishihama Y. Development of solubility screening methods in drug discovery. Yakugaku Zasshi. 122 (2002) 237-246
25. Huang L.-F., and Tong W.-Q. Impact of solid state properties on developability assessment of drug candidates. Adv. Drug Deliv. Rev. 56 (2004) 321-334
26. Glomme A., Maerz J., and Dressman J.B. Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities. J. Pharm. Sci. 94 (2005) 1-16
27. Bhattachar S.N., Wesley J.A., and Seadeek C. Evaluation of the chemiluminescent nitrogen detector for solubility determinations to support drug discovery. J. Pharm. Biomed. Anal. 41 (2006) 152-157
28. Tan H., Semin D., Wacker M., and Cheetham J. An automated screening assay for determination of aqueous equilibrium solubility enabling SPR study during drug lead optimization. Jala 10 (2005) 364-373
29. Corens D., Carpentier M., Schroven M., and Meerpoel L. Liquid chromatography-mass spectrometry with chemiluminescent nitrogen detection for on-line quantitative analysis of compound collections: advantages and limitations. J. Chromatogr. A. 1056 (2004) 67-75
30. Lane S., Boughtflower B., Mutton I., Paterson C., Farrant D., Taylor N., Blaxill Z., Carmody C., and Borman P. Toward single-calibrant quantification in HPLC. A comparison of three detection strategies: evaporative light scattering, chemiluminescent nitrogen, and proton NMR. Anal. Chem. 77 (2005) 4354-4365
31. Styslo-Zalasik M., and Li W. Determination of topiramate and its degradation product in liquid oral solutions by high performance liquid chromatography with a chemiluminescent nitrogen detector. J. Pharm. Biomed. Anal. 37 (2005) 529-534
32. Chen H., Zhang Z., McNulty C., Olbert C., Yoon H.J., Lee J.W., Kim S.C., Seo M.H., Oh H.S., Lemmo A.V., Ellis S.J., and Heimlich K. A high-throughput combinatorial approach for the discovery of a cremophor el-free paclitaxel formulation. Pharm. Res. 20 (2003) 1302-1308
33. Chen H., Zhang Z., Almarsson O., Marier J.-F., Berkovitz D., and Gardner C.R. A novel, lipid-free nanodispersion formulation of propofol and its characterization. Pharm. Res. 22 (2005) 356-361
34. Dai W.-G., Dong L.C., Li S., Pollock-Dove C., Chen J., Mansky P., and Eichenbaum G. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material. Int. J. Pharm. 336 (2007) 1-11
35. Mansky P., Dai W.-G., Li S., Pollock-Dove C., Daehne K., Dong L., and Eichenbaum G. Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: miniaturization and automation of solvent casting and dissolution testing. J. Pharm. Sci. 96 (2007) 1548-1563
36. Leuner C., and Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50 (2000) 47-60
37. Serajuddin A.T.M. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88 (1999) 1058-1066
38. Pouton C.W. Key issues when formulating hydrophobic drugs with lipids. Bull. Tech. Gattefosse 92 (1999) 41-50
39. Pouton C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 11 (2000) S93-S98
40. Schroeder H.G., and DeLuca P.P. In vitro precipitation of poorly soluble drugs from nonaqueous vehicles in human plasma. Bull. Parenter. Drug Assoc. 28 (1974) 1-14
41. Kostewicz E.S., Wunderlich M., Brauns U., Becker R., Bock T., and Dressman J.B. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J. Pharm. Pharmacol. 56 (2003) 43-51
42. Dai W.-G., Dong L.C., Shi X., Nguyen J., Evans J., Xu Y., and Creasey A.A. Evaluation of drug precipitation of solubility-enhancing liquid formulations using milligram quantities of a new molecular entity (NME). J. Pharm. Sci. 96 (2007) 2957-2969
43. Alsenz J., Meister E., and Haenel E. Development of a partially automated solubility screening (PASS) assay for early drug development. J. Pharm. Sci. 96 (2007) 1748-1762
44. Wyttenbach N., Alsenz J., and Grassmann O. Miniaturized Assay for Solubility and Residual Solid Screening (SORESOS) in Early Drug Development. Pharm. Res. 24 (2007) 888-898
45. Chen X.-Q., and Venkatesh S. Miniature Device for Aqueous and Non-aqueous Solubility Measurements During Drug Discovery. Pharm. Res. 21 (2004) 1758-1761
46. Gu C.-H., Rao D., Gandhi R.B., Hilden J., and Raghavan K. Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility. J. Pharm. Sci. 94 (2005) 199-208
47. Perng C.-Y., Kearney A.S., Palepu N.R., Smith B.R., and Azzarano L.M. Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens. Int. J. Pharm. 250 (2003) 147-156
48. Kossena G.A., Boyd B.J., Porter C.J.H., and Charman W.N. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. J. Pharm. Sci. 92 (2003) 634-648
49. Christensen J.O., Schultz K., Mollgaard B., Kristensen H.G., and Mullertz A. Solubilization of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. Eur. J. Pharm. Sci. 23 (2004) 287-296
50. Ljusberg-Wahren H., Seier Nielsen F., Brogard M., Troedsson E., and Muellertz A. Enzymatic characterization of lipid-based drug delivery systems. Int. J. Pharm. 298 (2005) 328-332
51. Dahan A., and Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm. Res. 23 (2006) 2165-2174
52. Porter C.J.H., and Charman W.N. In vitro assessment of oral lipid based formulations. Adv. Drug Deliv. Rev. 50 (2001) S127-S147
53. Porter C.J.H., Kaukonen A.M., Taillardat-Bertschinger A., Boyd B.J., O'Connor J.M., Edwards G.A., and Charman W.N. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. J. Pharm. Sci. 93 (2004) 1110-1121
54. Kaukonen A.M., Boyd B.J., Porter C.J.H., and Charman W.N. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. Pharm. Res. 21 (2004) 245-253
55. Humberstone A.J., and Charman W.N. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 25 (1997) 103-128
56. MacGregor K.J., Embleton J.K., Lacy J.E., Perry E.A., Solomon L.J., Seager H., and Pouton C.W. Influence of lipolysis on drug absorption from the gastrointestinal tract. Adv. Drug Deliv. Rev. 25 (1997) 33-46
57. Porter Christopher J.H., Trevaskis Natalie L., and Charman William N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6 (2007) 231-248
58. Dressman J.B., and Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 11 (2000) S73-S80
59. Horter D., and Dressman J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46 (2001) 75-87